Page last updated: 2024-12-10

phosphoribosylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3082052
CHEBI ID17284
SCHEMBL ID850803
MeSH IDM0053136

Synonyms (11)

Synonym
14050-66-9
d-ribofuranosylamine, 5-(dihydrogen phosphate)
phosphoribosylamine
CHEBI:17284
5-o-phosphono-d-ribofuranosylamine
[(2r,3s,4r)-5-amino-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
82197-76-0
d-riban, dihydrogen phosphate
SCHEMBL850803
DTXSID10903977
((2r,3s,4r)-5-amino-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate

Research Excerpts

Overview

PRA is a product of glutamine phosphoribosylpyrophosphate amidotransferase (PRPP-AT) and a substrate for glycinamide ribonucleotide synthetase (GAR-syn) It is the first enzyme in the de novo purine biosynthetic pathway.

ExcerptReferenceRelevance
"Phosphoribosylamine (PRA) is a product of glutamine phosphoribosylpyrophosphate amidotransferase (PRPP-AT) and a substrate for glycinamide ribonucleotide synthetase (GAR-syn), the first two enzymes in the de novo purine biosynthetic pathway. "( Investigation of the mechanism of phosphoribosylamine transfer from glutamine phosphoribosylpyrophosphate amidotransferase to glycinamide ribonucleotide synthetase.
Rudolph, J; Stubbe, J, 1995
)
2.01

Effects

ExcerptReferenceRelevance
"Phosphoribosylamine has a t1/2 = 38 s at 37 degrees C and pH 7.5."( Characterization and chemical properties of phosphoribosylamine, an unstable intermediate in the de novo purine biosynthetic pathway.
Cheng, YS; Otvos, JD; Schendel, FJ; Stubbe, J; Wehrli, S, 1988
)
1.26
"Phosphoribosylamine has a t1/2 = 38 s at 37 degrees C and pH 7.5."( Characterization and chemical properties of phosphoribosylamine, an unstable intermediate in the de novo purine biosynthetic pathway.
Cheng, YS; Otvos, JD; Schendel, FJ; Stubbe, J; Wehrli, S, 1988
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
ribose monophosphate
ribosylamine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (33.33)18.7374
1990's4 (16.67)18.2507
2000's6 (25.00)29.6817
2010's5 (20.83)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.20 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]